Danaher Corp DHR
We take great care to ensure that the data presented and summarized in this overview for DANAHER CORP is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding DHR
View all-
Vanguard Group Inc Valley Forge, PA59.8MShares$12.4 Billion0.25% of portfolio
-
Black Rock Inc. New York, NY50.5MShares$10.5 Billion0.29% of portfolio
-
State Street Corp Boston, MA27.4MShares$5.69 Billion0.25% of portfolio
-
Wellington Management Group LLP Boston, MA21.3MShares$4.43 Billion0.92% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD19MShares$3.94 Billion0.5% of portfolio
-
Capital International Investors Los Angeles, CA17.7MShares$3.67 Billion0.79% of portfolio
-
Geode Capital Management, LLC Boston, MA13.4MShares$2.78 Billion0.24% of portfolio
-
Morgan Stanley New York, NY11.7MShares$2.43 Billion0.19% of portfolio
-
Norges Bank Oslo, Q89.28MShares$1.93 Billion0.29% of portfolio
-
Northern Trust Corp Chicago, IL7.93MShares$1.65 Billion0.26% of portfolio
Latest Institutional Activity in DHR
Top Purchases
Top Sells
About DHR
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy. This segment also offers bioprocess technologies, consumables, and services; and filtration, separation, and purification technologies to the pharmaceutical and biopharmaceutical, food and beverage, medical, and life sciences companies, as well as universities, medical schools and research institutions, and various industrial manufacturers. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology, molecular, acute care, and pathology diagnostics products. This segment offers clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, industrial, and natural resource applications. This segment also provides instruments, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia.
Insider Transactions at DHR
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Feb 24
2025
|
Christopher Bouda VP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
285
-3.81%
|
$60,135
$211.14 P/Share
|
Feb 24
2025
|
Montgomery Julie A Sawyer Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
618
-11.23%
|
$130,398
$211.14 P/Share
|
Feb 24
2025
|
Georgeann Couchara SVP, Human Resources |
SELL
Payment of exercise price or tax liability
|
Direct |
197
-4.68%
|
$41,567
$211.14 P/Share
|
Feb 24
2025
|
Christopher Paul Riley Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
348
-3.03%
|
$73,428
$211.14 P/Share
|
Feb 24
2025
|
Jose Carlos Gutierrez Ramos SVP, Chief Science Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
586
-4.52%
|
$123,646
$211.14 P/Share
|
Feb 07
2025
|
Alan G Spoon Director |
SELL
Open market or private sale
|
Direct |
550
-0.45%
|
$113,300
$206.46 P/Share
|
Feb 07
2025
|
Alan G Spoon Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,928
+3.14%
|
$231,752
$59.34 P/Share
|
Feb 03
2025
|
Brian W Ellis Senior Vice President - GC |
SELL
Payment of exercise price or tax liability
|
Direct |
5,677
-28.06%
|
$1,214,878
$214.26 P/Share
|
Feb 03
2025
|
Matthew Mc Grew EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,345
-31.78%
|
$1,999,830
$214.26 P/Share
|
Feb 03
2025
|
Rainer Blair President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
20,030
-29.8%
|
$4,286,420
$214.26 P/Share
|
Feb 03
2025
|
Christopher Paul Riley Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
3,074
-21.1%
|
$657,836
$214.26 P/Share
|
Feb 03
2025
|
Daniel Raskas SVP - Corporate Development |
SELL
Payment of exercise price or tax liability
|
Direct |
4,701
-30.88%
|
$1,006,014
$214.26 P/Share
|
Jan 30
2025
|
Brian W Ellis Senior Vice President - GC |
SELL
Open market or private sale
|
Direct |
5,700
-21.98%
|
$1,276,800
$224.13 P/Share
|
Jan 30
2025
|
Brian W Ellis Senior Vice President - GC |
BUY
Exercise of conversion of derivative security
|
Direct |
5,700
+18.02%
|
$330,600
$58.59 P/Share
|
Nov 26
2024
|
Daniel Raskas SVP - Corporate Development |
SELL
Open market or private sale
|
Direct |
26,318
-63.35%
|
$6,211,048
$236.59 P/Share
|
Nov 26
2024
|
Daniel Raskas SVP - Corporate Development |
BUY
Exercise of conversion of derivative security
|
Direct |
26,318
+38.78%
|
$1,526,444
$58.59 P/Share
|
Nov 25
2024
|
Daniel Raskas SVP - Corporate Development |
SELL
Open market or private sale
|
Direct |
8,370
-35.47%
|
$1,992,060
$238.0 P/Share
|
Nov 21
2024
|
Matthew Mc Grew EVP & Chief Financial Officer |
BUY
Discretionary transaction
|
Indirect |
1,318
+11.5%
|
$309,730
$235.05 P/Share
|
Nov 21
2024
|
Christopher Bouda VP, Chief Accounting Officer |
BUY
Discretionary transaction
|
Indirect |
75
+10.78%
|
$17,625
$235.05 P/Share
|
Nov 21
2024
|
Mitchell P Rales Chairman of Exec. Committee |
SELL
Bona fide gift
|
Direct |
616
-0.04%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 23.3K shares |
---|---|
Exercise of conversion of derivative security | 183K shares |
Discretionary transaction | 1.39K shares |
Payment of exercise price or tax liability | 57.4K shares |
---|---|
Open market or private sale | 244K shares |
Bona fide gift | 31.4K shares |